Cognitive Impairment in Parkinson's Disease: Tools for Diagnosis and Assessment

被引:146
|
作者
Kulisevsky, Jaime [1 ]
Pagonabarraga, Javier
机构
[1] Hosp Santa Creu & Sant Pau, Movement Disorders Unit, Dept Neurol, Barcelona 08025, Spain
关键词
Parkinson's disease; cognition; dementia; neuropsychological; scale; DEMENTIA-RATING-SCALE; MENTAL-STATE-EXAMINATION; COMMUNITY POPULATION; PROGRESSION; VALIDATION; DISORDER; VALIDITY; DEFICITS; BATTERY; PROFILE;
D O I
10.1002/mds.22506
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Cognitive impairment (Cl) and dementia are frequent and debilitating features associated with Parkinson's disease (PD). Formal neuropsychological examination is required to ascertain the degree and pattern of CI over the course of the disease. The use of different tools may explain heterogeneous data obtained from studies to date. Normative data for extensively used scales [Mattis Dementia Rating Scale (MDRS), Mini-Mental State Examination (MMSE)] is incomplete in PD populations. According to sample characteristics, statistical analyses, and methodological quality, 33 studies using scales not specific to PD (MDRS, MMSE, Cambridge Cognitive Assessment, FAB) or PD-specific scales (Mini-Mental Parkinson, Scales for Outcomes of Parkinson's disease-Cognition, Parkinson's Disease-Cognitive Rating Scale, and Parkinson Neuropsychometric Dementia Assessment) were eligible for the critical analysis of their appropriateness to assess cognition in PD. Of the four scales specifically designed for PD, the SCOPA-COG and the PD-CRS have undergone extensive and rigorous validation processes. While the SCOPA-COG mainly. assesses "frontal-subcortical" cognitive defects, the PD-CRS also assesses "instrumental-cortical" functions, allowing better characterization of the different patterns of Cl that may be present in PD from the earliest stages. The MMP and PANDA scales were designed as brief screening tests for Cl and have not yet been subjected to extensive clinimetric evaluations. Further research on PD-specific tools seems mandatory to help establish accurate cut-off scores for the diagnosis of mild PDD, detect cognitive profiles more prone to the future development of dementia, and allow comparisons between different descriptive or interventional studies. (C) 2009 Movement Disorder Society
引用
收藏
页码:1103 / 1110
页数:8
相关论文
共 50 条
  • [31] Is all cognitive impairment in Parkinson’s disease “mild cognitive impairment”?
    Saül Martínez-Horta
    Jaime Kulisevsky
    Journal of Neural Transmission , 2011, 118 : 1185 - 1190
  • [32] Is all cognitive impairment in Parkinson's disease "mild cognitive impairment"?
    Martinez-Horta, Sauel
    Kulisevsky, Jaime
    JOURNAL OF NEURAL TRANSMISSION, 2011, 118 (08) : 1185 - 1190
  • [33] Mild cognitive impairment in Parkinson’s disease: the Parkinson’s disease cognitive study (PACOS)
    Roberto Monastero
    Calogero Edoardo Cicero
    Roberta Baschi
    Marco Davì
    Antonina Luca
    Vincenzo Restivo
    Chiara Zangara
    Brigida Fierro
    Mario Zappia
    Alessandra Nicoletti
    Journal of Neurology, 2018, 265 : 1050 - 1058
  • [34] Mild cognitive impairment in Parkinson's disease: the Parkinson's disease cognitive study (PACOS)
    Monastero, Roberto
    Cicero, Calogero Edoardo
    Baschi, Roberta
    Davi, Marco
    Luca, Antonina
    Restivo, Vincenzo
    Zangara, Chiara
    Fierro, Brigida
    Zappia, Mario
    Nicoletti, Alessandra
    JOURNAL OF NEUROLOGY, 2018, 265 (05) : 1050 - 1058
  • [35] Mild cognitive impairment in Parkinson's disease
    Petrovic, M.
    Stefanova, E.
    Svetel, M.
    Dragasevic, N.
    Kostic, V.
    Knezevic, Z.
    PARKINSONISM & RELATED DISORDERS, 2007, 13 : S55 - S55
  • [36] Homocysteine and cognitive impairment in Parkinson's disease
    Javier Martin-Fernandez, Jose
    Carles-Dies, Rafael
    Canizares, Francisco
    Parra, Soledad
    Aviles, Francisco
    Villegas, Irene
    Morsi-Hassan, Ossama
    Fernandez-Barreiro, Andres
    Trinidad Herrero, M.
    REVISTA DE NEUROLOGIA, 2010, 50 (03) : 145 - 151
  • [37] Mild cognitive impairment and Parkinson's disease
    Driver-Dunckley, ED
    Caviness, JN
    Adler, CH
    Sabbagh, M
    Connor, D
    Shill, H
    Hernandez, J
    Evidente, VGH
    NEUROLOGY, 2005, 64 (06) : A201 - A201
  • [38] Treatment of cognitive impairment in Parkinson's disease
    Williams-Gray, C. H.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S143 - S144
  • [39] MRI and Cognitive Impairment in Parkinson's Disease
    Ibarretxe-Bilbao, Naroa
    Tolosa, Eduardo
    Junque, Carme
    Marti, Maria-Jose
    MOVEMENT DISORDERS, 2009, 24 (14) : S748 - S753
  • [40] Characterizing Cognitive Impairment in Parkinson's Disease
    Bailey, Meagan
    Goldman, Jennifer G.
    SEMINARS IN NEUROLOGY, 2017, 37 (02) : 167 - 175